Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by jimmyhorizonon Jul 22, 2022 8:28am
126 Views
Post# 34842536

RE:RE:Remember this

RE:RE:Remember this
biorun wrote: if you are calculating present value of all future royalties and payments, maybe ... but if you think you are going to see a cheque that big as an upfront payment you are completely dilusional. and abbvie will likely not share their total valuation of the deal, so you are just setting false expectations.


bio, this is going too far now.
if anyone is raising false expectations here, who is it on this board?

sakinny has done nothing other than refer to a source.

in the latest "in depth" analysis dated 27 june 2022 by prc partners which was done in collaboration with sirona, it states:

"We estimate that AbbVie will take around 10% of the $8B USD skin-lightening
market, which equates to an estimated $40M USD in annual royalty payments for
Sirona Biochem. $680M USD in total over 17 years."




<< Previous
Bullboard Posts
Next >>